Health-care companies rose as traders rotated out of artificial-intelligence bets into sectors that lagged in the second quarter.
Galderma shares fell after the Swiss skincare specialist failed to obtain approval from the U.S. Food and Drug Administration for its latest product to rival AbbVie's Botox for the second time.
French drug maker Ipsen agreed to buy Swiss biotechnology company Memo Therapeutics in a deal that could exceed $800 million, adding to its suite of rare-disease drugs.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
